$EPZM - On a watchlist - possibly going to get a trading opportunity. A Biotech high-risk / high-reward type.Morgan Stanley upgrades Epizyme to Overweight ahead of lymphoma dataMorgan Stanley analyst David Lebowitz upgraded Epizyme to Overweight from Equal Weight with a price target of $22, up from $12. The stock in after-hours trading is up 3%, or 40c, to $15.70. The analyst expects data this weekend at the American Society of Hematology meeting to bolster confidence in tazemetostat for follicular lymphoma. The data, which will include more mature results and median progression-free survival in the mutant patients, should be "incrementally positive," Lebowitz tells investors in a research note. The analyst raised his 2021 adjusted tazemetostat sales estimate to $23M from $18M and 2026 estimate to $733M from $377M. $EPZM, Epizyme, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page